VC-backed AbCellera buys Dualogics’ bispecific platform

AbCellera, a Vancouver, British Columbia-based developer of therapeutic antibodies, has acquired the OrthoMab bispecific platform of Dualogics.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this